| 摘要 |
The present invention relates to a leukaemia-treatment pharmaceutical composition, and more specifically to a Myc protein activity inhibitor comprising a 4-quinolinone derivative and to a cancer-treatment pharmaceutical composition which uses the 4-quinolinone derivative as an active ingredient, wherein the leukaemia-treatment pharmaceutical composition according to the present invention suppresses Myc/Max/DNA complex formation and so induces cell cycle arrest, thereby giving the advantage that the composition can suppress the growth of various human leukaemia cell strains, and can advantageously be used to prevent and treat leukaemia. |
